• KDventures portfolio company Modus Therapeutics raised SEK 7.6 million in a directed share issue to fund sevuparin development in 2027.
• The company issued 20,000,000 shares at SEK 0.38 each, before transaction costs.
• Proceeds earmarked for manufacturing supply, severe-malaria research collaboration work, and business development tied to phase 2a CKD anemia readout.
• KDventures’ stake in Modus Therapeutics stands at 51% following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.